AbbVie strikes $10.9 billion deal for Apogee Therapeutics
22/06/2026 12:02
AbbVie strikes $10.9 billion deal for Apogee Therapeutics June 22 (Reuters) - AbbVie ABBV.N will acquire biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)